TABLE 1.
Provenance of Candida strains
| Study and isolate | Species | Source/commenta |
|---|---|---|
| Preliminary broth dilution study | ||
| 01-132-1299 | C. albicans | Clinical isolate, Westmead Hospital, Sydney, Australia |
| 01-1741796 | C. albicans | Clinical isolate, Westmead Hospital, Sydney, Australia |
| 01-234-0858 | C. albicans | Clinical isolate, Westmead Hospital, Sydney, Australia |
| Y123 | Clavispora lusitaniae | MSD, source unknown |
| 97-291-0929 | C. lusitaniae | Clinical isolate, Westmead Hospital, Sydney, Australia |
| 99-167-0481 | C. lusitaniae | Clinical isolate, Westmead Hospital, Sydney, Australia |
| 00-049-3110 | Trichosporon beigelii | Clinical isolate, Westmead Hospital, Sydney, Australia |
| Microbroth dilution study | ||
| ATCC 90028 | Candida albicans | |
| Y105 | C. albicans | MSD, heterozygous for semidominant mutation in C. albicans FKSb; reduced susceptibility to caspofungin |
| Y111 | C. albicans | MSD, clinical (blood) isolate, reduced susceptibility to caspofungin |
| TS3 | C. albicans | Clinical isolate, Westmead Hospital, Sydney, Australia |
| 03-226-3110 | C. albicans | Clinical isolate, Westmead Hospital, Sydney, Australia |
| Y114 | Candida glabrata | MSD, clinical (blood) isolate from Chile |
| 03-257-1430 | C. glabrata | Clinical (blood) isolate, Westmead Hospital, Sydney, Australia |
| Y117 | Candida krusei | MSD, clinical (blood) isolate, Buffalo, New York |
| Y118 | C. krusei | MSD, clinical (stool) isolate, Germany; reduced susceptibility to caspofungin |
| 9235 | C. parapsilosis | Clinical (blood) isolate, CIDMLS |
| 9236 | C. parapsilosis | Clinical (blood) isolate, CIDMLS |
| 8336 | C. guilliermondii | Clinical (blood) isolate, CIDMLS |
| 8333 | C. guilliermondii | Clinical (blood) isolate, CIDMLS |
a
MSD, Merck, Sharp and Dohme; CIDMLS, Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead Hospital, Sydney, Australia.